News Hub | News Direct

Graft Polymer records "year of growth" against "somewhat challenging" backdrop

Graft Polymer (UK) PLC

Graft Polymer (UK) PLC (LSE:GPL) independent non-executive director Alex Brooks speaks to Thomas Warner from Proactive following the release of final results for calendar year 2022 - a year he describes as a "year of growth" despite it being a "somewhat challenging year" for its core customer base. Brooks goes on to talk about what's been achieved so far in 2023, adding that he "remains optimistic that market conditions are getting better" and expects another year of strong revenue growth. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 02, 2023 06:23 AM Eastern Daylight Time

Video

News Release

Ondine Biomedical shares potential impact of photodisinfection study on public health and safety

Ondine Biomedical Inc

Ondine Biomedical President and CTO Nicolas Loebel joins Natalie Stoberman from the Proactive studios to share how the latest results from its photodisinfection concept study can impact food safety in Canada and beyond. Loebel says the results of this study produced up to a 99.999% elimination of pathogens commonly found on hard surfaces in meat processing facilities, as well as those directly located on fresh-cut chicken, beef, and pork meat. Loebel adds these results could have direct impacts on community well-being and industry profitability by increasing consumer confidence in addition to reducing the strain on public health from food-borne illnesses. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

May 01, 2023 09:08 AM Eastern Daylight Time

Video

FS is on a Mission to Unleash Human Creativity. With a Relaunch of its Trend Forecasting Platform, the Future’s Looking Brighter for all Creators

Fashion Snoops

Earlier forecast timelines, dedicated specialty areas, advanced color inspiration, smoothly integrated with AI-powered market tracking and design tools — empowers creators to map their path ahead with extraordinary clarity. FS (Fashion Snoops) announces the relaunch of its popular future forecasting platform. The new rendition streamlines the product creation process; makes it more intuitive, interactive, and creatively fulfilling. Putting power into the hands of the creators, the FS platform provides advanced inspiration aimed to spark future ideas and help track what's happening in the market. Its range of custom tools enable subscribers to gather creative intelligence across retail, runways, trade shows, and social media. Most importantly, they help curate those discoveries into cutting-edge creative strategies and concepts. All in a format that is easy to customize, share, or export into design software. "The problem for creators today is not a lack of information, but rather an overload of it. That's where we come in, ” explains Itay Arad, Co-founder and CEO at FS. "Instead of just offering more, we present our clients with incisive, inspiring content that is easy to find and ready to provoke action." As a company with a purpose to unleash human creativity, the FS forecasting platform offers creatives a way to find joy and inspiration in the product development process. Once again. Feeding their imagination and passion for creating products that aren't driven solely by data or recent fads but by genuine innovation. "We realized that the market is desperately looking for a way to rekindle inspiration,” says Lilly Berelovich, Co-founder and Chief Creator at FS. “We are seeing too many brands and retailers trading in curiosity for a false sense of certainty. Relying so heavily on data and past successes that creativity and innovation are quickly diminishing. It's a catch-22 situation.” Berelovich continues, “Everyone is trying to figure out what consumers want, while the consumers are simply looking to be surprised and excited by newness from the brands... from our commitment to unleashing human creativity, we aim to help the market break this exhausting cycle.” Here are the highlights of features and tools on the renewed FS futures platform: TRACK AREA: FS subscribers can keep their finger on the pulse of what's happening across retail, social media, runways, and trade shows. FS's unique sorting and filtering algorithms make identifying trends and discovering inspiration for their future assortments fun and easy. EXPANDED CATEGORIES: Due to popular demand, the FS team has invested in and grown the offering for Activewear, Swimwear, and Intimates. Creators in these areas now have a section that speaks their language and focuses on their unique needs. COLOR TOOLS: FS's powerful suite of color tools includes a dynamic palette builder, an AI-enhanced runway color tracker, and the ability to search the platform's images by color. Aided by these tools and FS's in-depth color reports, subscribers can create their own original color palettes or use the ones built by FS as a starting point. Individual color chips and entire palettes can now be easily exported and uploaded to design software like Adobe Photoshop and InDesign. PATTERN + GRAPHICS AREA: Inspiration across markets or an individual design category can be found while accessing FS's popular pattern and graphics reports in one convenient place. ASSET GALLERY: FS team's editorial content, which includes mood images, bespoke videos, original art, CADs, and color palettes, is easy to browse through, save, and share. MY FS AREA: Subscribers can access all their saved multimedia content (reports, videos, images, palettes, individual color chips) and drag-and-drop pieces to curate visually compelling mood and concept boards. ABOUT FS For over 22 years, FS (Fashion Snoops) has been a leading force in trend forecasting. Our curious team of experts serves clients in over 50 countries from the worlds of fashion, accessories, home decor, beauty, wellness, and other consumer-facing industries. With a powerful-yet-intuitive digital platform and decades of industry insight, FS is known for collaborating closely with clients. From boutique brands to Fortune 500 companies, we are helping to chart their path to a thriving business. Find your creative futures at fashionsnoops.com Contact Details Fashion Snoops Ashleigh Ralfe +44 7824 393164 ashleigh@fashionsnoops.com Company Website http://fashionsnoops.com/

May 01, 2023 09:00 AM Eastern Daylight Time

Image

Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries

TalkMarkets on EVGN

Evogene ( EVGN ) oversees five subsidiaries: Biomica, agPlenus, Lavie Bio, Castera, and Canonic. Each company uses Evogene’s unique artificial intelligence (AI) platform to develop products for different human medical needs and the agricultural industries. Their CPB platform, which stands for computational predictive biology, provides efficient ways to map plant phenotypes and microbial genomes. Their subsidiaries employ this AI technology to improve plant genetics, commercial fertilizers, and human medicines. Evogene produces revenue via its subsidiaries in two ways. It brings in benchmark and licensing payments from companies, who use its products and research. The main function of each subsidiary is to conduct research within their specialties using the CPB platform. The company also makes revenues from at-the-market sales of some of its products, including medical cannabis and wheat seed stimulant. Evogene’s stock price has been on the long-term downtrend which mirrors the trend of current market conditions. Global economic destabilization, ongoing bank crises, and historical interest rate hikes have diligently wrecked ideal market conditions for all stocks. These conditions may get worse and promise to stick around for a while. Buy ratings must be considered under these volatile conditions. Evogene has managed to stay afloat and its financial performance has continued to improve throughout this bearish period. Revenues are increasing for the company and each of its subsidiaries have new developments in their pipelines. The company’s stock price is trading at or near its all-time low and is undervalued at the moment. The situation may present an opportunity for investment with an eye to long-term growth. Updates on Evogene’s subsidiaries Lavie Bio uses Evogene’s MicroBoost AI engine to innovate agricultural supplements, like growth stimulates and fertilizer. The company recently received a $10 million investment from ICL (ICL) under a SAFE agreement. The company will collaborate with ICL to develop new agricultural products, here fertilizer. ICL is a global manufacturer of products made with specialty minerals. Lavie Bio currently has a growth stimulant on the market called Thrivus. Their spring wheat seed treatment, a microbiome-based bio-inoculant, was released on the market in the US during 2022 and sold out initially. The product increases summer wheat yields by up to four bushels per acre. The company plans to expand sales of Thrivus to other countries, like Canada and Europe. Lavie Bio also has a bio-fungicide, up for approval by the US EPA, which fights fruit rot and powdery mildew. It hopes to bring the fungicide to market in 2024 with focus on treating grape harvests. Biomica uses Evogene’s MicroBoose AI to develop microbiome-based medical treatments. The company currently has three drug candidates, which are undergoing clinical research and trials. BMC-128 is being developed to treat solid tumors in humans. The drug candidate is currently being tested on cancer patients in a Phase 1 clinical trial for human safety. The company hopes to begin Phase 1b/2 in 2024. The company’s second drug candidate, BMC333, is a microbiome therapeutic for treating inflammatory bowel disease. The drug, consisting of a combination of four live bacteria strains, has been tested on animals and found to reduce inflammation and tissue damage along the GI tract. The company plans a phase 1 trial in 2024. Biomica’s third drug candidate, BMC426, is being considered for the treatment of irritable bowel syndrome. The company has completed discovery with its candidate and has moved into pre-clinical trials. Biomica recently received a $20 million investment round led by Shanghai Healthcare Capital. The deal received regulatory approval from China today and allows for future investment rounds. AgPlenus uses Evogene’s ChemPass AI technology to develop commercial herbicides, insecticides, and fungicides. The company is currently focused on developing an herbicide which is effective on herbicide resistant weeds in commercial crops. AgPlenus’s current candidate, APH1, is an herbicide for treating unwanted weeds in large commercial grow operations. The company is in a partnership with Corteva ( CTVA ) for developing new herbicides. AgPlenus discovers new herbicide candidates, while Corteva tests them and ultimately licensing them. AgPlenus has other products under development, including a fungicide. Casterra, Evogene’s newest subsidiary, uses the company’s GeneRaptor AI technology to innovate novel castor plant varieties. Castor seeds processed into oil are used worldwide for bio-diesel and are currently in high demand. The company recently signed an agreement with a European energy company to provide castor seeds and technical support for a set of cultivation sights in Africa. Casterra has another agreement with Titan Castor Farms in Zambia for production and distribution of its castor seeds. The company feels that castor seeds may be the next major catalyst for its financial performance and shareholders. Canonic uses Evogene’s GeneRaptor AI technology to map and breed cannabis genetics for medical applications. The cannabis strains are bred to have specific traits for treating certain medical conditions. The company has recently released its second-generation cannabis products in the Israeli medical cannabis market. These new genetics were perfected at Canonic’s cannabis research facility and boast a high THC potency of 24%. The products consist of a selection of dried flowers and THC oil tinctures. Evogene’s financial performance Over the last four quarters, revenues have increased for Evogene. In their Q3-2022 filings, the company reported revenues of $466K showing a more than 200% increase YoY. In their recent Q4-2022 filings, the company reported revenues of $660K more than 100% increase YoY and a 40% increase from last quarter. The company also reported its 2022 fiscal year performance. Revenue increased more than 80% from $930K (2021) to 1.675 million (2022). Evogene receives revenues through benchmark and licensing payments from companies usings its products and research. The company also has revenues from medical cannabis sales by Canonic and from sales of Lavio Bio’s wheat stimulant. The company expects future revenues from Casterra and its recent agreements to supply castor seed and support. The market consensus for Q1-2023 revenue estimates is $2 million, a significant increase from previous quarters. Whether or not the company hits that estimate, its revenues should continue to grow from quarter to quarter. Evogene reported a net loss of $3.8 million for Q4-2022, which is less than previous quarters. The company has a cash position of $31.860 million and receives enough money in receivables to continue its business and research strategy for some time. Evogene is set to receive $3.5 million from Bayer ( BAYRY ) for their seed trait collaboration agreement. The company’s largest operational cost is funding research and development. The company has no bank debt. The company requires about $4 million per quarter to operate. Evogene competes with such companies as Schödinger ( SDGR ), Ginkgo Networks ( DNA ), Exscientia ( EXAI ), and Relay Therapeutics ( RLAY ). Evogene is currently undervalued Evogene’s stock price has been trading under a $1 per share since September 2022. In January, the price began an uptrend towards a dollar per share, but in February a new down trend emerged. The price now sits near its all-time low around $.63 per share. There is a possibility that the company’s stock will have to undergo a reverse split to meet the minimum price requirements of $1 per share. So long as the stock price is low, the company remains undervalued. Its stock is currently trading at.49x NTM Total Enterprise Value / Revenue. The situation may present an opportunity to begin a long-term investment in the company’s stock. Evogene’s financials are sound and its research and product pipelines are robust. Greater market volatility may be the largest barrier in giving the company a strong buy rating for the time being. Conclusion Keep your eye on Evogene’s financial performance and research developments from its five subsidiaries. The company has been perfecting AI technology for a long time and its applications have produced innovative products. The company will continue to raise revenue numbers with its at the market products and benchmarks payments. Evogene has plenty of incoming receivables to fuel its research agenda and business strategy. The company’s stock is at an all-time low, while the company’s financial performance is on par with expectations. The metrics show that the company is currently undervalued and an investment opportunity may soon present itself. Larger market conditions will help decide if a long-term investment is tenable. Originally published at TalkMarkets. Related Articles: Biomica Announces Closing Of $20 Million Financing Round Led By Shanghai Healthcare Capital Evogene Offers An Excellent Risk/Reward Ratio More By This Author: Up In Smoke: Cannabis In A Bear Market Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and otherwise represent their own assessments and opinions. Authors are not compensated by the subject companies in any way. This article is also part of our IR Insights Initiative in which articles about participating companies can receive greater visibility. To learn more click here. Author Disclosure: No position in EVGN at the time of writing. Contact Details TalkMarkets ir@talkmarkets.com

April 28, 2023 09:00 AM Eastern Daylight Time

Synairgen CEO lays out plans for 2023 and beyond

Synairgen PLC

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talks to Proactive following the release of full year results for calendar year 2022 - a year he says was "quite challenging at times." Marsden discusses the UK-based respiratory company's clinical development plan to take the SNG001 drug through Phase 3 trials and registration. The drug is being developed to help patients with respiratory viruses such as influenza virus, RSV, and SARS- CoV-2. The plan was formulated after a year of data collection and consultation with experts. He also highlights the company's relatively strong cash position, which he says will "allow [Synairgen] to get on with" its planned work schedule. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

C4X Discovery Holdings making "slight pivot" to anti-inflammatory treatments

C4X Discovery Holdings PLC

C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix speaks to Thomas Warner from Proactive after releasing half-year results for the six months ending 31 January 2023. Dix gives his highlights from the interim results before turning his focus to what he describes as a "slight pivot" to anti-inflammatory treatments. C4X has a portfolio of anti-inflammatory targets, including a molecule for COPD, and four or five new anti-inflammatory targets in the pipeline, which will be revealed in due course. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

Creo Medical Group FY22 results and recent funding - Proactive Research Analyst

Creo Medical Group PLC

Proactive Research Analyst John Savin gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Savin talks about the company's recent performance and key products, before moving on to look at how it is positioned for the future. He also touches on a recent placing that generated a net £32 million. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

ImmuPharma "looking forward" to upcoming FDA meetings

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio, following what he calls a "very busy time" for the specialty biopharmaceutical company. He discusses the latest developments and next steps for the P140 platform, highlighting the importance of two upcoming meetings with the US FDA. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

Maureen McBride Named CEO of UNOS

United Network for Organ Sharing

Maureen McBride, Ph.D., has been named CEO of United Network for Organ Sharing (UNOS), the mission-driven, non-profit organization that serves as the nation’s organ donation and transplant system — the Organ Procurement and Transplantation Network (OPTN) — under contract with the federal government. “We conducted an exhaustive nationwide search for a new CEO and were pleased to find that the most qualified candidate is Dr. McBride,” said UNOS Board President Jerry McCauley, M.D., who chaired the Search Committee. “She impressed the Committee with her innovative spirit, clear-eyed vision of transformational change at UNOS and knowledge of the challenges facing the organ donation and transplantation community today. Since taking over as Interim CEO seven months ago, Dr. McBride has shown that she embodies a much-needed change in approach and operations at UNOS. She has put the organization on a new trajectory by increasing transparency and communication with the organ donation and transplantation community, regulators, Congress and the public, and advancing new initiatives to modernize and improve the organ donation and transplant system to benefit patients and ensure public trust.” Under McBride’s leadership, UNOS released an Action Agenda earlier this year, a comprehensive set of improvements in critical areas of the transplant system, including transparency, accountability, equity, transportation and modernization. McBride has worked for UNOS since 1995. She has served as Interim CEO since October 2022 and before that, as Chief Operating Officer managing the OPTN contract. She was also the organization’s Director of Research from 2006 to 2014 and contributed to more than 50 research manuscripts and publications. As CEO, she directs the efforts of 450 UNOS staff to ensure that the nation’s organ donation and transplant network efficiently and fairly serves the needs of transplant candidates and recipients, living donors and donor family members, and professionals in the field. She will be the first woman to lead the organization. “I am humbled, thrilled and energized to be selected to serve as CEO of UNOS,” McBride said. “As long as there are patients in desperate need of organs, we have more work ahead of us. As we move forward in our mission to save more lives, I look forward to leading UNOS during a time of immense change. As I said in my first official remarks as Interim CEO: we can do better, we must do better, and we will do better. We are excited to show our ongoing commitment to saving lives, how we are best situated to help usher in proposed improvements and how our expertise should remain an integral part of the system. Additionally, I am excited to continue working with UNOS’ other non-OPTN business lines to enhance and grow our organization.” In selecting McBride, the UNOS Corporate Affairs Committee agreed this is a pivotal moment in the organization’s history. They cited her leadership skills and proven ability to navigate organizational change both internally and externally as the lifesaving work continues and as UNOS prepares to respond to the federal government’s upcoming RFPs for the new OPTN contract. This includes her institutional knowledge of UNOS and the entire organ donation and transplant community; her experience in the field; her commitment to clear and frequent communication to build trust, understanding and consensus; and her unquestioned commitment to the organization and its mission to save as many lives as possible through organ donation and transplantation. She received her bachelor of science in mathematics from Loyola College in Maryland and her Ph.D. in biostatistics from Virginia Commonwealth University, Medical College of Virginia. McBride has served as the Executive Director of the OPTN since October 2022. She will begin her new role with UNOS immediately. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

April 27, 2023 02:36 PM Eastern Daylight Time

Image